entertainment -WSS

entertainment

author：explore 2025-09-30 02:15:42 - browse：375

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Reframing the conversation around gain

WSS

ALS advocates say criticism of new drugs misses bigger picture

A rare thyroid diagnosis led to unexpected, all

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Trump surgeon general acknowledges mistakes during Covid

Florida babysitter arrested over hot car death, authorities say

Hey, doctors: Don't be no

explore

entertainment

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

NIH nominee Bertagnolli will get October confirmation hearing

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

House transparency, PBM reform bill gains bipartisan support

At least 13 dead in Texas as scorching temps continue

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

At least 13 dead in Texas as scorching temps continue

A rare thyroid diagnosis led to unexpected, all

Hepatitis C has a cure — but many Americans still lack access to it

What is artificial intelligence? Experts weigh in

focus

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Trump surgeon general acknowledges mistakes during Covid

Why the advice to take all your antibiotics may be wrong

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Why the advice to take all your antibiotics may be wrong

Illumina names Agilent executive as new CEO

Wikipedia

focus

leisure time

focus